difference from semaglutide and tirzepatide caused roughly half as many patients to stop treatment because of gastrointestinal side effects as semaglutide. In the first major head-to-head obesity trial, GI side effects caused treatment discontinuation in: Tirzepatide GLP-1 Medications for Weight Loss:

Long-term follow-up data shows sustained weight loss when patients continue the medication, with weight regain occurring after discontinuation

Hng dn s dng: Ngi ln t 18 tui tr ln: Dng 1 vin mi ngy cng hoc khng cng ba n (c ngha l ung lc i hay no u c) hoc dng theo ch nh ca bc s

Do not skip doses for longer than recommended without consulting your doctor

All analyses were conducted using Pyspark and SparkR on Databricks and the R software package

Clinical trials have demonstrated reductions in hemoglobin A1c levels and weight loss that vary by dose and populationwith higher doses (such as Wegovy 2.4 mg) achieving approximately 15% weight loss in obesity trials, with more modest effects at lower doses used for diabetes

Common Side Effects Some common side effects that people may experience include issues such as mild nausea or more severe symptoms like vomiting and diarrhea